NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X 
MENLO PARK, Calif., Oct. 20, 2017 -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) will hold its quarterly conference call to discuss its Third Quarter 2017 Financial Results on Thursday, November 2, 2017, at 4:30pm Eastern Time.
The call will be webcast and may be accessed at Pacific Biosciences’ website at: http://investor.pacificbiosciences.com/.
Date: November 2, 2017
Time: 4:30pm ET
Listen via Internet: http://investor.pacificbiosciences.com/
Toll-free: 888.366.7247
International: 707.287.9330
Audience Passcode: 3297738
Replay: http://investor.pacificbiosciences.com
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences' products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences' technology provides high accuracy, ultra-long reads, uniform coverage, and is the only DNA sequencing technology that provides the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.
Contact: Pacific Biosciences
Trevin Rard
650.521.8450
[email protected]
